A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. - Wikidata - wikimedia - TriplyDB

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

http://www.wikidata.org/entity/Q44938984

about

Endothelin receptor antagonists for pulmonary arterial hypertension Endothelin receptor antagonists for pulmonary arterial hypertension Hypoxia upregulates PGI-synthase and increases PGI₂ release in human vascular cells exposed to inflammatory stimuli Inhaled treprostinil: a therapeutic review Pharmacotherapy of systemic sclerosis Pulmonary hypertension associated with COPD Health-related quality of life in patients with pulmonary arterial hypertension Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.Guanylate cyclase stimulators for pulmonary hypertension Pulmonary Hypertension Due to Common Respiratory Conditions: Classification, Evaluation and Management Strategies Insight into Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (PAH-CHD): Classification and Pharmacological Management from a Pediatric Cardiological Point of View Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis The limits of oral therapy in pulmonary arterial hypertension management The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series)Pulmonary hypertension: diagnostic and therapeutic challenges Pathobiology of pulmonary arterial hypertension and right ventricular failure Drug treatment of pulmonary hypertension in children Pulmonary hypertension in renal disease: epidemiology, potential mechanisms and implications Pharmacotherapy for pulmonary hypertension Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)Pulmonary arterial hypertension: a comparison between children and adults Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy Recent advances in the management of pulmonary arterial hypertension Breaking Down the Barriers: Why the Delay in Referral for Pulmonary Arterial Hypertension?Treatment-related biomarkers in pulmonary hypertension Hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs Treprostinil for the treatment of pulmonary arterial hypertension Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue Sex hormones are associated with right ventricular structure and function: The MESA-right ventricle study Temperature variations around medication cassette and carry bag in routine use of epoprostenol administration in healthy volunteers Quality of life, safety and efficacy profile of thermostable flolan in pulmonary arterial hypertension Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension Nitrite Prevents Right Ventricular Failure and Remodeling Induced by Pulmonary Artery Banding Bloodstream infections in patients given treatment with intravenous prostanoids.

P2860

Q24200714-D12A02F8-AE05-4CCF-B6B7-FF1A06808A48 Q24240009-B87830A2-8A5F-42AE-A67F-FD68809D2F45 Q24339277-CBF1573C-5445-421E-B6E3-D56721580448 Q24601864-41B5AF63-1B24-41E8-8294-32C1DB8E4E0F Q24629481-B93B6A6B-10EF-4823-89A8-3452466C29F1 Q24797500-17B1966A-830A-4D01-81F8-9A62CE55FEBE Q24814151-218A1E21-C1DF-4195-BD8C-B9654839F877 Q24815216-D64C980D-2C85-454E-8176-DFE7F8AD0415 Q26470534-EE7441F3-EE39-43C7-A88A-A32A8452F64D Q26738405-59F04DF1-75E9-47F4-8124-957068F0731A Q26749283-B994AF59-D5FC-4738-8170-2990BA59B71D Q26772960-54B9CFE1-18D7-40E2-849E-95CCABF2D6CD Q26773209-D18D646B-68D7-4BBC-8777-DEB77C69E10F Q26781681-7AE43414-9BDD-496F-846F-ED7D51F84163 Q26796434-97D13E79-581E-4A81-9606-88C30F67A421 Q26821779-B7D56184-362A-4F4C-AF2C-410E7D0E1DB7 Q26996078-1305EDE1-EBF2-4955-B660-2CBD7B50DFF6 Q26996772-633B41AE-8D4C-4C7A-A97B-03ED664FAF92 Q27022763-EB60763E-1684-4D82-842F-EEE8917205C0 Q27023074-EB386F35-611E-41ED-AAC1-8273A03598C1 Q27497418-621B3924-5B06-43D9-9BB7-F51E87905268 Q27687320-68331354-5002-438D-9D71-3FAC68B3CEF4 Q28069093-D367E779-0960-491E-AA1B-684188223F0B Q28072562-72991BBA-A224-4B0F-8005-6C9F1DB332EB Q28072649-B433E353-1214-434C-AD49-D946977532BE Q28075707-B2E19C3B-C5D4-44CF-978D-12FB47A674D1 Q28078660-F4B5C038-0131-47F6-8AD7-CA8AACD165D5 Q28081276-01433A9C-030F-4CF2-A415-2DB5E12BFB5F Q28083099-2F7D0644-9A7C-448E-9E7D-D919F7A24988 Q28218337-0C6AF2DF-A19E-4B10-85C7-09A75D82719C Q28281899-9FA72426-36EA-4F62-8267-06C8673E8AE5 Q28346468-CFC2A8D2-7C09-420B-9506-66C97E508476 Q28346517-68315794-968D-4EBA-BC64-E3F2BF89E087 Q28364280-C1B6DEE7-9215-4BE8-B28E-1D3455AEF1A7 Q28388122-06EE1409-D285-49CD-BE99-6ACFFED097EC Q28484599-A7D16F33-5AE8-4DC1-BC63-E8B7C052F8DB Q28544778-E526BFB9-F8A9-410A-A79B-300F0A759923 Q28582609-AF377297-EC60-46EA-9CBD-7E2EBF0ABF7F Q29248756-0F75AD8C-AF73-4EC0-AA83-C2E0A54AB8AA Q30228937-CC69562B-3BF7-406D-9CF6-09833298B948

P2860

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

http://www.wikidata.org/entity/Q44938984

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年学术文章

@wuu

1996年学术文章

@zh-cn

1996年学术文章

@zh-hans

1996年学术文章

@zh-my

1996年学术文章

@zh-sg

1996年學術文章

@yue

1996年學術文章

@zh

1996年學術文章

@zh-hant

name

A comparison of continuous int ...... rimary pulmonary hypertension.

@en

A comparison of continuous intravenous epoprostenol

@nl

type

label

A comparison of continuous int ...... rimary pulmonary hypertension.

@en

A comparison of continuous intravenous epoprostenol

@nl

prefLabel

A comparison of continuous int ...... rimary pulmonary hypertension.

@en

A comparison of continuous intravenous epoprostenol

@nl

P1433

Q44938984-6FFB644C-AE8F-40FB-A26D-A2EFE49BD06B

P1476

Q44938984-FEFA438F-084C-4ACE-9C66-930D543AFE86

P2093

Q44938984-03115E58-7070-4B1B-8A11-0B80B84AC882

Q44938984-178D146D-3841-428A-BDE6-B33AED6EB6FF

Q44938984-1E2A61C1-0E0F-449C-B27E-0CA3080A0EAB

Q44938984-31376FDD-8BD4-44CF-B172-699CE60AF404

Q44938984-3F2D6515-4A43-428A-B5F4-D2EAF791E4A3

Q44938984-555FC991-3632-4EC3-834C-FD37270683C9

Q44938984-56F187D2-D43B-4D86-AB3F-CD6F3BC28498

Q44938984-6627768E-C9BC-467E-A467-2CA5F1DDA886

Q44938984-8B9D9419-1506-4B6F-A76C-B3B57CE5C11D

Q44938984-9E290BCE-48F9-4B4E-837E-39C105445895

P304

Q44938984-6A3B5B8A-A73F-4D79-A31B-486CB31CE546

P31

Q44938984-D8075025-20E4-4C8B-8104-B36652B42A25

P356

Q44938984-DD17CD86-EFC8-4C38-982D-28FC7EF1B7EF

P407

Q44938984-4373FB2A-A696-4FC9-BC12-1C190D6706C0

P433

Q44938984-5316C061-6F47-4D24-9FCE-B49EB466E426

P478

Q44938984-E447037E-32B7-4F22-97FB-53F5E58A1AF8

P577

Q44938984-2E77BA0A-646F-4839-ABD4-BC9F5C9F624A

P5875

Q44938984-820FB16B-E886-4DDA-91A4-DE620936781F

P698

Q44938984-8454F96F-DBF5-4C9D-8625-8E1F671FACB3

P921

Q44938984-2D5D0FE8-90D5-4374-B9E7-1336B1F5BB71

P356

NEJM199602013340504

P1433

The New England Journal of Medicine

P1476

A comparison of continuous int ...... rimary pulmonary hypertension.

@en

P2093

B F Uretsky

http://www.w3.org/2001/XMLSchema#string

B H Brundage

http://www.w3.org/2001/XMLSchema#string

B M Groves

http://www.w3.org/2001/XMLSchema#string

C A Keller

http://www.w3.org/2001/XMLSchema#string

D B Badesch

http://www.w3.org/2001/XMLSchema#string

D Langleben

http://www.w3.org/2001/XMLSchema#string

D Shortino

http://www.w3.org/2001/XMLSchema#string

J W Crow

http://www.w3.org/2001/XMLSchema#string

L J Rubin

http://www.w3.org/2001/XMLSchema#string

L M Clayton

http://www.w3.org/2001/XMLSchema#string

P304

296-301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJM199602013340504

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

334

http://www.w3.org/2001/XMLSchema#string

P577

1996-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14668519

http://www.w3.org/2001/XMLSchema#string

P698

8532025

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension